N/A
N=30
Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Bottom Line
View on ClinicalTrials.gov: NCT01953575 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mucosal Impedance (Device); Upper Endoscopy (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Jun 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Esophageal Mucosal Impedance (MI) |
1457; 3463; 4225; 1713; 5110; 4741 | — |
Summary
Do patients with eosinophilic esophagitis have baseline increased esophageal mucosal impedance?
And will treatment that reverses esophageal eosinophilia in patients, correct abnormalities in mucosal impedance?
Eligibility Criteria
Inclusion criteria
- Adults ages 18-90 undergoing clinically indicated upper endoscopy
- Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy
- Patients undergoing clinically indicated upper endoscopy for indications other than dysphagia or Gastroesophageal reflux disease (GERD) with normal appearing esophageal mucosa.
Exclusion criteria
- Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy
- Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
- Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
Data sourced from ClinicalTrials.gov (NCT01953575). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.